CUV — Clinuvel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$381.23m
- AU$131.12m
- AU$94.02m
Brief: Clinuvel Pharmaceuticals Says Philippe Wolgen Returns As MD
Brief: Clinuvel Pharmaceuticals Renews Share Buy-Back Program
Brief: Clinuvel Pharmaceuticals Says CEO Philippe Wolgen To Take Temporary Leave
Brief: Clinuvel Pharmaceuticals Signs Distribution Agreement For Scenesse With Diligens Salud SA
Brief: Clinuvel Pharmaceuticals Says Scenesse Validated And Accepted For Review
Brief: Clinuvel Pharmaceuticals Says Decision To Strategically Prioritise Three Key Clinical Programs
Australia's Clinuvel Pharmaceuticals jumps 11% on higher FY24 profit
Brief: Clinuvel Pharmaceuticals Declared Fully Franked Final Dividend Of A$0.05
Brief: Clinuvel Pharmaceuticals Posts FY Pretax Profit AUD 50.7 Mln
Australia's Clinuvel Pharmaceuticals soars on positive study results
Australia's Clinuvel Pharmaceuticals rises on positive update on drug development
Brief: Clinuvel Pharmaceuticals Says Afamelanotide Received Positive Opinion For Orphan Drug Designation From EMA
Morningstar says premature to assign value to Australia's Clinuvel Pharmaceuticals' clinical program
Brief: Clinuvel Pharmaceuticals Enters Strategic Partnership With Valentech Pharma
Brief: Clinuvel Pharmaceuticals Says European Medicines Agency Grants Orphan Drug Designation For Afamelanotide In Xeroderma Pigmentosum
Brief: Clinuvel Pharmaceuticals Says CFO Darren Keamy Will Conclude Role On 30 June 2024
Australia's Clinuvel Pharmaceuticals gains most in over 3 weeks on buyback
Brief: Clinuvel Pharmaceuticals To Start 12-Mnth On-Market Share Buy-Back Program Of 1.5 Mln Ordinary Shares
Morningstar upbeat on Australia's Clinuvel Pharmaceuticals potential